,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,157 Church Street,19th floor,New Haven,CT,06510,United States,203 533 7082,https://www.bioasis.us,Biotechnology,Healthcare,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.","{'maxAge': 1, 'name': 'Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C.', 'age': 64, 'title': 'Exec. Chairman, CEO & Pres', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 154221, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0,0.474487,-0.074,50000,50000,101867,48050,48050,0.0,0.0,0,0,587560,0.0037,0.184,2.181189,0.0057,0.021695,0.0,0.0,USD,2350909,0.0,77784439,79414000,0.02052,0.0,-0.034,1646006400,1677542400,1669766400,-2875838,-0.03,-0.05,8.727,-0.789,PNK,EQUITY,BIOAF,BIOAF,BIOASIS TECHNOLOGIES INC,Bioasis Technologies Inc.,1293805800,America/New_York,EDT,-14400000,0.0037,none,156515,0.002,-2980693,2213593,0.047,0.106,269376,0.004,-0.80583,-1188430,-310482,-1936522,2.948,-2.59664,0.0,-11.411591,CAD,
1,157 Church Street,19th floor,New Haven,CT,06510,United States,203 533 7082,https://www.bioasis.us,Biotechnology,Healthcare,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.","{'maxAge': 1, 'name': 'Mr. David P. Jenkins', 'age': 60, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 92528, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0,0.474487,-0.074,50000,50000,101867,48050,48050,0.0,0.0,0,0,587560,0.0037,0.184,2.181189,0.0057,0.021695,0.0,0.0,USD,2350909,0.0,77784439,79414000,0.02052,0.0,-0.034,1646006400,1677542400,1669766400,-2875838,-0.03,-0.05,8.727,-0.789,PNK,EQUITY,BIOAF,BIOAF,BIOASIS TECHNOLOGIES INC,Bioasis Technologies Inc.,1293805800,America/New_York,EDT,-14400000,0.0037,none,156515,0.002,-2980693,2213593,0.047,0.106,269376,0.004,-0.80583,-1188430,-310482,-1936522,2.948,-2.59664,0.0,-11.411591,CAD,
2,157 Church Street,19th floor,New Haven,CT,06510,United States,203 533 7082,https://www.bioasis.us,Biotechnology,Healthcare,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.","{'maxAge': 1, 'name': 'Mr. Graeme  Dick', 'title': 'Director of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0,0.474487,-0.074,50000,50000,101867,48050,48050,0.0,0.0,0,0,587560,0.0037,0.184,2.181189,0.0057,0.021695,0.0,0.0,USD,2350909,0.0,77784439,79414000,0.02052,0.0,-0.034,1646006400,1677542400,1669766400,-2875838,-0.03,-0.05,8.727,-0.789,PNK,EQUITY,BIOAF,BIOAF,BIOASIS TECHNOLOGIES INC,Bioasis Technologies Inc.,1293805800,America/New_York,EDT,-14400000,0.0037,none,156515,0.002,-2980693,2213593,0.047,0.106,269376,0.004,-0.80583,-1188430,-310482,-1936522,2.948,-2.59664,0.0,-11.411591,CAD,
3,157 Church Street,19th floor,New Haven,CT,06510,United States,203 533 7082,https://www.bioasis.us,Biotechnology,Healthcare,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.","{'maxAge': 1, 'name': 'Mr. Aaron  Elton', 'title': 'Director of Marketing', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0,0.474487,-0.074,50000,50000,101867,48050,48050,0.0,0.0,0,0,587560,0.0037,0.184,2.181189,0.0057,0.021695,0.0,0.0,USD,2350909,0.0,77784439,79414000,0.02052,0.0,-0.034,1646006400,1677542400,1669766400,-2875838,-0.03,-0.05,8.727,-0.789,PNK,EQUITY,BIOAF,BIOAF,BIOASIS TECHNOLOGIES INC,Bioasis Technologies Inc.,1293805800,America/New_York,EDT,-14400000,0.0037,none,156515,0.002,-2980693,2213593,0.047,0.106,269376,0.004,-0.80583,-1188430,-310482,-1936522,2.948,-2.59664,0.0,-11.411591,CAD,
4,157 Church Street,19th floor,New Haven,CT,06510,United States,203 533 7082,https://www.bioasis.us,Biotechnology,Healthcare,"Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.","{'maxAge': 1, 'name': 'Dr. Mei Mei Tian', 'title': 'VP & Head of External Research', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0037,0.0,0.474487,-0.074,50000,50000,101867,48050,48050,0.0,0.0,0,0,587560,0.0037,0.184,2.181189,0.0057,0.021695,0.0,0.0,USD,2350909,0.0,77784439,79414000,0.02052,0.0,-0.034,1646006400,1677542400,1669766400,-2875838,-0.03,-0.05,8.727,-0.789,PNK,EQUITY,BIOAF,BIOAF,BIOASIS TECHNOLOGIES INC,Bioasis Technologies Inc.,1293805800,America/New_York,EDT,-14400000,0.0037,none,156515,0.002,-2980693,2213593,0.047,0.106,269376,0.004,-0.80583,-1188430,-310482,-1936522,2.948,-2.59664,0.0,-11.411591,CAD,
